Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | TMPRSS6 | Q8IU80 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745706 | 1.00 | MMP7 (0.47) | MMP7F2TMPRSS6PTPN1MAPK1 | |
| SCHEMBL3740543 | 0.91 | MMP2 (0.50) | F2TMPRSS6PTPN1ALDH1A1MAPT | |
| SCHEMBL3740541 | 0.91 | MMP2 (0.50) | F2TMPRSS6PTPN1ALDH1A1MAPT | |
| SCHEMBL3745612 | 0.90 | F2 (0.49) | F2TMPRSS6PTPN1ALDH1A1MAPT | |
| SCHEMBL3745613 | 0.90 | F2 (0.49) | F2TMPRSS6PTPN1ALDH1A1MAPT | |
| SCHEMBL3730063 | 0.87 | NPY5R (0.56) | F2TMPRSS6PTPN1MAPK1ALDH1A1 | |
| SCHEMBL3730065 | 0.87 | NPY5R (0.56) | F2TMPRSS6PTPN1MAPK1ALDH1A1 | |
| SCHEMBL3740533 | 0.85 | BMP1 (0.51) | F2TMPRSS6PTPN1MAPK1ALDH1A1 | |
| SCHEMBL3740529 | 0.85 | BMP1 (0.51) | F2TMPRSS6PTPN1MAPK1ALDH1A1 | |
| SCHEMBL3745711 | 0.85 | SRC (0.46) | MMP7F2TMPRSS6MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | claimed |
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | MMP7 1033/4885F2 4506/4885TMPRSS6 1963/4885 |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | MMP7 1033/4885F2 4506/4885TMPRSS6 1963/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | MMP7 1033/4885F2 4506/4885TMPRSS6 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.